Irish drug technology business Alkermes reported a net loss of $14.8 million for its fiscal third quarter to the end of December last but upgraded forecasts for the full year.

Alkermes, which transferred its headquarters to Ireland after acquiring Elan’s Athlone-based drug technology business, saw revenues almost treble in the period – the first full quarter for the combined business – to $125.6 million. The company said full year revenues were likely to come in about 10 per cent ahead of forecasts at between $370 and £400 million, with full year net losses projected at $70-$82 million.